Javascript must be enabled to continue!
Regulatory circuits and antibody responses
View through CrossRef
AbstractConsideration of the interactions among cells and cell products involved in regulating antibody responses leads us to suggest that such interactions are organized into several discrete circular series (circuits) integrated with one another by virtue of shared circuit components. We see these circuits as individually concerned with particular aspects of regulation (carrier‐specific, idiotype‐specific, etc.), but together constituting an integrated, self‐governing system capable of regulating all aspects of antibody production and assuring the ordedy progress of the response (sequential idiotype representation, affinity maturation, isotype representation, overall or selective non‐ responsiveness, etc.).To illustrate how a circuit‐based regulatory system could be constructed and expected to operate, we describe four integrated circuits here: a core regulatory circuit that determines whether a given idiotype will or will not be produced and three auxiliary regulatory circuits that respond to antigen and serum antibody (idiotype) levels by switching the core regulatory circuit into a suppression or “help” mode. These circuits incorporate the idiotype‐anti‐idiotype recognition system basic to the Jerne network theory but also provide for the operation of other cognitive systems that enable specific interactions between individual circuit elements (B cells, antibody, the various suppressor and helper T cells, macrophages and soluble regulatory products). As an integrated unit, the circuits constitute a detailed “working” model that depends on relatively few assumptions and is consistent with the known interactions between elements and the known properties of responses.
Title: Regulatory circuits and antibody responses
Description:
AbstractConsideration of the interactions among cells and cell products involved in regulating antibody responses leads us to suggest that such interactions are organized into several discrete circular series (circuits) integrated with one another by virtue of shared circuit components.
We see these circuits as individually concerned with particular aspects of regulation (carrier‐specific, idiotype‐specific, etc.
), but together constituting an integrated, self‐governing system capable of regulating all aspects of antibody production and assuring the ordedy progress of the response (sequential idiotype representation, affinity maturation, isotype representation, overall or selective non‐ responsiveness, etc.
).
To illustrate how a circuit‐based regulatory system could be constructed and expected to operate, we describe four integrated circuits here: a core regulatory circuit that determines whether a given idiotype will or will not be produced and three auxiliary regulatory circuits that respond to antigen and serum antibody (idiotype) levels by switching the core regulatory circuit into a suppression or “help” mode.
These circuits incorporate the idiotype‐anti‐idiotype recognition system basic to the Jerne network theory but also provide for the operation of other cognitive systems that enable specific interactions between individual circuit elements (B cells, antibody, the various suppressor and helper T cells, macrophages and soluble regulatory products).
As an integrated unit, the circuits constitute a detailed “working” model that depends on relatively few assumptions and is consistent with the known interactions between elements and the known properties of responses.
Related Results
Procedure for Western blot v1
Procedure for Western blot v1
Goal: This document has the objective of standardizing the protocol for Western blot. This technique allows the detection of specific proteins separated on polyacrylamide gel and t...
IgM antibody to hepatitis C virus in acute and chronic hepatitis C
IgM antibody to hepatitis C virus in acute and chronic hepatitis C
To assess possible role of testing for IgM-specific antibody in the diagnosis and monitoring of patients with hepatitis C, we tested sera from 14 patients with acute and 97 patient...
Mesoscale Modeling of a Nucleosome-Binding Antibody (PL2-6): Mono- vs. Bivalent Chromatin Complexes
Mesoscale Modeling of a Nucleosome-Binding Antibody (PL2-6): Mono- vs. Bivalent Chromatin Complexes
ABSTRACTVisualizing chromatin adjacent to the nuclear envelope (denoted “epichromatin”) by in vitro immunostaining with a bivalent nucleosome-binding antibody (termed monoclonal an...
New Generation of Electronic Components and How They Influence Printed Circuit Boards
New Generation of Electronic Components and How They Influence Printed Circuit Boards
The approach to reduce the costs of electronic circuits will be the transition of LSI‐circuits to VLSI‐circuits, introducing another order of magnitude to the complexity and densit...
SARS-CoV-2 antibody changes in patients receiving COVID-19 convalescent plasma from normal and vaccinated donors
SARS-CoV-2 antibody changes in patients receiving COVID-19 convalescent plasma from normal and vaccinated donors
ABSTRACT
Background and Objectives
Vaccination has been shown to stimulate remarkably high antibody levels in donors who have r...
Retrospective analysis of the clinical significance of Ro52/TRIM21 antibody and specific antinuclear antibody patterns by indirect immunofluorescence
Retrospective analysis of the clinical significance of Ro52/TRIM21 antibody and specific antinuclear antibody patterns by indirect immunofluorescence
Objectives: To determine the clinical significance of Ro52 protein/tripartite motif-containing 21 antibody and specific antinuclear antibody patterns using indirect immunofluoresce...
The effect of the pandemic on autoantibody rates in the general population
The effect of the pandemic on autoantibody rates in the general population
Objectives: The study aimed to investigate the possible effects of coronavirus disease 2019 (COVID-19) on autoantibodies.
Patients and methods: Samples of 89,108 individuals (29,0...
Treatment for Covid-19 with SARS-CoV-2 neutralizing antibody BRII-196(Ambavirumab) plus BRII-198(Lomisivir): a retrospective cohort study
Treatment for Covid-19 with SARS-CoV-2 neutralizing antibody BRII-196(Ambavirumab) plus BRII-198(Lomisivir): a retrospective cohort study
Abstract
Background
Monoclonal antibody therapy for Covid-19 springs up all over the world and get some efficiency. This research aims to explore th...

